Actively Recruiting
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-05
133
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries. Its incidence is estimated at 17.8/100,000 in subjects over 50 years old (and 46/100,000 in subjects over 70 years old). This disease remains a severe pathology due in particular to its vascular, ophthalmological, neurological, cardiac and aortic complications. In case of suspected CAG, management is a real therapeutic emergency. Indeed, only corticosteroid therapy started as early as possible can prevent the occurrence of these complications. The gold standard for the diagnosis of CAG has long been the temporal artery biopsy, but imaging is now considered as a 1st line diagnostic examination for the diagnosis of CAG according to the EULAR 2018 recommendations. Notably, temporal artery MRI has excellent sensitivity and specificity for diagnosis. However, the high diagnostic performance of MRI has been achieved by performing 3D T1 black blood and fat saturation sequences in high resolution (\<0.7mm), which are not accessible in all centers in France and worldwide. The realization of identical sequences with a lower resolution could allow a greater generalization of these sequences and improve the diagnostic management of GCA patients, including in non-expert centers. The objective of our study is to investigate the diagnostic performance of several 3D T1 black blood and fat saturation sequences for the diagnosis of GCA.
CONDITIONS
Official Title
Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years of age
- Referred for imaging with injected MRI for suspected GCA
- Suspicion of GCA based on at least three major criteria or two major and one minor criteria
- Major criteria include: age over 50 years; recent onset headache; jaw, tongue claudication or swallowing disorders; visual problems such as blindness, double vision, or blurred vision during the first week of treatment; sedimentation rate at 1st hour over 50 and/or CRP over 8 mg/l
- Minor criteria include: scalp hypersensitivity or nodules away from the temporal artery; temporal artery abnormalities on palpation; facial pain or swelling; general signs such as fever over 38°C, weight loss over 10%, anorexia, malaise, or fatigue
- Consent to participate in the study
- Affiliated with or beneficiary of a social security plan
You will not qualify if you...
- Newly diagnosed malignant disease within one year prior to inclusion
- Active infectious disease
- Autoimmune diseases including Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, periarteritis nodosa
- Systemic corticosteroid therapy for more than 10 days at high dose (over 0.5 mg/kg/day of prednisone)
- Contraindication to MRI
- Patient under legal protection measures
- Pregnant or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Fondation Adolphe de Rothschild
Paris, France
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here